PharmaTalkRadio

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: 

• Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherence
• How pharma can use drug delivery device data with predictive analytics to forecast demand and optimize production
• Enabling patient-centric design and innovation by analyzing device usage data

To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:

• How pharma and suppliers can improve sustainability
• Creating designs with lower carbon footprints relative to fabrication and materials
• Circular recycling models

To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.

To learn more about the PODD Conference, please visit PODDConference.com.

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.

To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: 

• Overcoming primary container and autoinjector challenges for liquid-liquid delivery
• Improving upon dual chamber reconstitution devices
• Finding the right approach to navigate supply chain

To learn more about the PODD Conference, please visit PODDConference.com.

About this Podcast:
 As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.

Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.

More specifically, Sean discusses:  

• Separating short-term, mid-term and long-term costs and benefits of implementing AI 

• What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI 

• AI deployed for bottom-line revenue versus internal team efficiency 

• What the first steps would be for sponsors to successfully integrate AI across their enterprise 

About this podcast:
Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. 

Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction.

About this podcast:
In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.

More specifically, Ms Gershkowitz focuses on:

• Defining role standards and recruiting the right talent 
• Co-creatin research with patient communities and developing patient-centered outcomes
• Generating metrics that demonstrate the impact on R&D

When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.

More specifically:

• Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplication
• Designing trials around real patients rather than ideal patients
• Better understanding the objectives of the study and asking the questions that achieve those objectives
• Better partnering with patients and PIs

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: 

• Advantages and disadvantages to platform approaches for device development
• Opportunities to overcome technical limitations
• Approaches to bring a platform into multiple product design history files
• Regulatory hurdles
• Assessing business case and getting organizational buy-in

To learn more about the PODD Conference, please visit Drug-Delivery.org.